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Poster Session II 137Conclusions:Kinetics of T-reg andT-cells engraftment were inde-
pendent, underlying the need for assessing chimerism levels among
each T-cells and T-regs in patients given nonmyeloablative condi-
tioning. Our data did not show any significant correlation between
T-reg levels and occurrence of chronic GVHD thus far. Data in-
cluding higher number of patients will be presented.374
PUVA THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) OF
THE SKIN
Furlong, T., Appelbaum, F.R., Carpenter, P.A., Deeg, J., Doney, K.,
Flowers, M.E.D., Kiem, H.-P., Martin, P.J., Mielcarek, M.,
Nash, R.A., Storb, R. Fred Hutchinson Cancer Research Center, Seattle,
WA.
Glucocorticoids remain the standard for initial treatment of acute
GVHD. However, toxicities and immunosuppression are severe
and steroid-sparing strategies would be desirable. Between 5/96
and 4/07 we treated 55 patients with isolated skin GVHDwith me-
thoxsalen plus ultraviolet-A light therapy (PUVA), with the objec-
tive of avoiding systemic immunosuppressive therapy. Patients
were treated with PUVA three times/week initially at doses of
0.25 J/m2, with exposure increased 0.25 J/m2 per treatment as clin-
ically indicated. The median patient age was 48 (range 4–71) years.
Twenty-six received a calcineurin inhibitor plus mycophenolate
mofetil for GVHD prophylaxis, 24 received a calcineurin inhibitor
plus methotrexate, and 5 received other regimens. Sixteen had re-
lated donors (1 HLA-mismatched), and 39 had unrelated donors
(15 HLA-mismatched). The median onset of GVHD was 26 days
after transplant, and the median start time of PUVA was 43 days.
Forty-five patients received PUVA as initial therapy for acute
GVHD, and 10 patients received PUVA for recurrent GVHD after
discontinuation of prednisone administration. At the start of PUVA
therapy, 31 patients (56%) had rash involving . 50% body surface
area (BSA), 19 (35%) had rash 26–50% BSA and 5 (9%) had rash#
25% BSA. The median number of PUVA treatments was 13 (range
2–26). Sixteen patients (29%) had complete responses after amedian
of 14 (range 8–26) PUVA treatments and required no subsequent
systemic immunosuppressive therapy for treatment of acute
GVHD. Twelve patients required systemic therapy after starting
PUVA for treatment of isolated gastrointestinal GVHD, although
8 of these patients had cleared or improved skin rash before starting
systemic therapy. Twenty-four patients (44%) required systemic
immunosuppressive therapy after starting PUVA for treatment of
skinGVHD (18) or skin plus gastrointestinal GVHD (6). Three pa-
tients had evidence of skin GVHD when PUVA was discontinued
early due to readmission to the hospital or discharge home. Only
four patients required secondary systemic therapy for treatment of
acute GVHD.Thirty-one of 52 patients who could be evaluated de-
veloped chronicGVHD.Thirty-seven patients remain alive at ame-
dian of 753 days after transplant. Overall, 24 of 55 patients (44%)
responded to PUVAwith resolution or improvement of rash. These
results suggest that PUVA can be effective in treating skin GVHD
and in reducing the need for systemic immunosuppressive treat-
ment.375
THE ANALYSIS OF CHRONIC GVHD AFTER CORD BLOOD TRANSPLANTA-
TION IN COMPARISON WITH BONE MARROW TRANSPLANTATION
Seo, S., Uchida, N., Yamamoto, H., Takagi, S., Tsuji, M., Kato, D.,
Matsuno, N., Masuoka, K., Wake, A., Taniguchi, S. Toranomon Hospi-
tal, Tokyo, Japan.
Backgrounds: Umbilical cord blood can be an alternative stem
cell source for the patients with hematological malignancies requir-
ing allogeneic stem cell transplantation. However, little is known
about graft versus leukemia/lymphoma (GVL) effect in cord blood
transplantation (CBT). Here, we analyzed chronic GVHD
(cGVHD) in CBT compared with that in BMT and evaluated the
relevance between cGVHD andGVL.Patients/Methods:We ret-rospectively studied 162 patients who had been free from disease
progression for more than 100 days after either unrelated BMT (n
5 75) or CBT (n 5 87) at Toranomon Hospital from January
2002 to December 2006. Median age of the patients was 52 years
old (BMT vs CBT: 49 vs 53). Underlying diseases were acute leuke-
mia (n 5 88), myelodysplastic syndrome (n 5 17), lymphoma (n 5
39) and others (n 5 18). Conditioning regimens were mainly com-
posed of Fludarabine 125–180 mg/m2 with several combinations of
Melphalan 80–140 mg/m2, Busulfan 8–16 mg/kg and/or total body
irradiation (4–8 Gy).Results:TheMedian observation period after
the transplantationwas 612 days (range, 109–1944). The cumulative
incidence of cGVHD was 84% in BMT and 62% in CBT (p 5
0.09). The severity of cGVHD was analyzed based on its type; lim-
ited or extensive. In CBT, the percentage of the former type was
34% (vs 25% in BMT) and the latter was 23% (vs 48% in BMT).
High-risk disease (p 5 0.03) and preceding acute GVHD(p 5
0.03) are related to the occurrence of cGVHD. RICBT tended to
increase cGVHD compared to CBT using BU/CY or CY/TBI reg-
imen. Multivariative analysis showed that cGVHD increased over-
all survival rate (p\0.01) and suppressed recurrence of the disease
(p\0.01). During observation period, no patients after CBT were
died of cGVHD. Discussion: We demonstrated that cGVHD in
CBT is tolerable compared with that in BMT and that the occur-
rence of cGVHD could result in good prognosis. Our analysis
also suggested that CBT could have GVL effect as well as BMT.376
PERSISTENT RECIPIENT ANTIGEN-PRESENTING CELLS IN HUMAN HE-
MATOPOIETIC STEM CELL TRANSPLANTATION: IDENTIFICATION OF
A DERMAL SUBSET THAT OUTLIVES EPIDERMAL LANGERHANS CELLS
Haniffa, M.1, Ginhoux, F.2, Abel, M.2, Bullock, S.1, Alshemali, S.1,
Merad, M.2, Collin, M.P.1,2. 1Newcastle University, Newcastle upon
Tyne, United Kingdom; 2Mount Sinai School of Medicine, New York.
Graft versus host disease (GVHD), a lethal complication of he-
matopoietic stem cell transplantation (HSCT), is initiated by recip-
ient antigen presenting cells (APC) priming donorT cells. The skin,
a commonly affected organ, contains diverse APC including hetero-
geneous dermal dendritic cells (DC) whose contribution to GVHD
is not well understood.
We have obtained 22 pairs of skin biopsies pre and post condi-
tioning (high dose BuCy or CyTBI and reduced intensity Flu/
Mel) and 85 biopsies at day 40, 100 and 365 post HSCT from pa-
tients with sex-mismatched donors. Pre and post conditioning sam-
ples were digested and analysed with CD45, HLA-DR, CD14 and
CD1a antibodies in a single step Trucount protocol. Chimerism
was determined on cytospins of spontaneously migrated dermal
APC and collagenase digested dermal cells using sequential four-
colour confocal microscopy and X/Y fluorescence in situ hybridiza-
tion.
We find 3 populations of CD451 DR1 dermal cells: CD141
CD1a- fXIIIa-; CD141 CD1a- fXIIIa1; CD1a1 CD14- fXIIIa-.
Characterization of these cells in vitro shows that CD141 cells
are more adherent and phagocytic than CD1a1 cells and that the
fXIIIa1 component is in addition, heavily granulated with ingested
melanin. CD141 APC are resistant to depletion by conditioning
(210 pre/213 post; cells per mm2; P 0.86) compared with CD1a1
cells (201 pre/97 post; mean cells per mm2; P 0.03). Both are re-
duced in HSCT patients compared with controls (706 CD141
and 468 CD1a1 cells per mm2; both P 0.01).
Chimerism analysis at 40, 100 and 365 days post HSCT reveals
two strikingly different patterns of engraftment. CD1a1 and
CD141 fXIIIa- cells, obtained either bymigration or digestion, en-
graft rapidly in all patients, ahead of LC, reaching medians of 99%
and 100% donor, respectively, at day 40. In contrast, CD141
fXIIIa1 cells, which are obtained only from digested dermis, are
very slow to engraft in the absence of GHVD, reaching only 63%
median donor after high dose and 10%median donor chimerism af-
ter reduced regimens, at 1 year. Acute GVHD promotes engraft-
ment with 100% donor chimerism seen in nearly all patients at
day 100. Cell cycle analysis ndicates that these cells are not actively
synthesizing DNA, suggesting a different mode of survival com-
pared with persistent recipient LC.
